OncoCyte Corp (OCX)

[ALERTS100%to10000%GAIN]

OCX~~MONSTA FILLINGS https://ih.advfn.com/p.php?pid=nmona&article=77076490

https://ih.advfn.com/p.php?pid=nmona&article=77076450

[ALERTS100%to10000%GAIN]

above 2.00 will be awesome close

[halbroke1]

OCX $$$$ BIG POWER-HOUR..

[ALERTS100%to10000%GAIN]

OCX~~safety money,will run hard

[halbroke1]

OCX COULD CLOSE $4.00-$5.00 TODAY....

[ALERTS100%to10000%GAIN]

OCX~~MONSTA UPSIDE<<$10,000,000.00 dollars invested here per news

[ALERTS100%to10000%GAIN]

OCX~~AGREED,L2 is wild and institutions BUYING crazy

[halbroke1]

OCX $$$ COULD SEE $10+...MASSIVE NEWS TODAY !!!

[ALERTS100%to10000%GAIN]

OCX~~1.50 better buy ,MONDAY HUGE

[ALERTS100%to10000%GAIN]

OCX~~$1.30,monsta news OncoCyte Announces the Closing of a $10 Million Private Placement of Common Stock
Print
Alert
Oncocyte Corp. (AMEX:OCX)
Intraday Stock Chart
Today : Wednesday 28 March 2018

Click Here for more Oncocyte Corp. Charts.

OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer, today announced that it has closed a private placement of its common stock with two of its current investors. The purchase agreement for the private placement committed the investors to purchase 7,936,508 shares of common stock for $1.26 per share, for total gross proceeds of $10.0 million before deducting offering expenses. Of this amount, OncoCyte has received $8.0 million in gross proceeds from the sale of 6,349,206 shares of common, and one of the investors irrevocably committed to purchasing an additional 1,587,302 shares for gross proceeds of $2.0 million prior to April 30, 2018. OncoCyte intends to use the net proceeds from the offering for the continued development of its liquid biopsy diagnostic tests for the early detection of cancer, complementary acquisitions, working capital and other general corporate purposes.
Chardan Capital Markets, Inc. acted as sole placement agent for the offering.

The securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state or other jurisdiction's securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock to be issued and sold in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About OncoCyte Corporation

OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients. While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for detecting lung, breast and bladder cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein markers that differentially express in specific types of cancer.

Forward Looking Statements

Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) are forward-looking statements. These statements include those pertaining to the subsequent closing of $2.0 million, the use of proceeds from the private placement, implementation and results of research, development, clinical trials and studies, commercialization plans, future financial and/or operating results, and potential opportunities for OncoCyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, the need and ability to obtain future capital, and maintenance of intellectual property rights, and the need to obtain third party reimbursement for patients’ use of any diagnostic tests we commercialize. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly as such statements should be evaluated together with the many uncertainties that affect the business of OncoCyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in OncoCyte’s Securities and Exchange Commission filings. OncoCyte disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contacts:

EVC Group LLC
Matt Haines / Michael Polyviou
917-733-9297 / 732-933-2754
[e-mail] / [e-mail]

Financial Media Contact:

GIBSON Communications, LLC
Tom Gibson
201-476-0322
[e-mail]

[willlbone]

"inconsistent analytic results" Sell now.

[newguy49]

getting very tired of nothing happening in this stock. no liquid biopsy news at all. I am wondering if it was just all BS.
If any one reads this and you know anything please respond.
thanks, Bob

[poonch1ne]

That drop was BS, over a technical non event.

[newguy49]

WOW! 24% I like it, sure wish I knew for certain why now since it dropped 21% just a few days ago.

[DeepDive]

Since the largest shareholder is Biotime, the discussion is there.

[newguy49]

so what the heck happened? 21% drop and no news or comments.

[newguy49]

great day for our ocx. volume and price up.was a good week.
Is it possible we could be starting a period of price appreciation. how nice would that be. fingers crossed!

[Tim501]

Things are heating up, but you'd never know it from this board.

The dip recently to once again below $4 was painful for the longs, but fortunately some of us bought even more. The funding round was coming and some insiders knew more $3.25s would be issued. I certainly hope that is the last time we'll see $3.25s - with just the $5.50 warrants above them.

The stock is impossible to trade a decent large block. Nibbling, even slightly, takes the sellers off the ask. It's been like that since it got back up above $4. Before the dip, you could hit the ask and eventually they'd lower it - getting it down so the $3.25 new warrants didn't look too much like a big give away.

The last two days have been telling. Eight weeks to get through $6 last time -- this week it took about 4k shares to breach the level. And lastly we saw a 40cent uptick in the last minute today on about 12k. The A/D line is pretty impressive.

My big question is how quickly can OCX generate meaningful revenues from international distribution and partnerships while they pursue US reimbursements? It's nice that hardly anyone follow this board b/c it means I'm ahead of the party. But can any one of the five of you reading this board talk about my question above?

I am counting on OCX having at least one announcement lined up with an international partner to be signed and released following the completion of the two outstanding validation trials. So how quickly will partnerships come once they are clear to make and sell?

With that said - I look forward to the day when we have 1000 messages on this board. Then we'll know the word is out. I am stunned by how so few folks are following or even aware of this nifty unique investment opportunity.

Good luck to all longs. We've got a phenomenal management team working for us and I for one am getting excited about how well they are delivering.

Tim

[newguy49]

nice to see this move up a little on over 2x volume. given where OCX is at in the production cycle I would have thought it might have moved sooner. Better late than never, now lets keep it going!

[DeepDive]

OncoCyte Receives $5.74 Million in Proceeds from Exercise of Warrants


ALAMEDA, Calif., July 25, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the receipt of $5.74 million through the cash exercise of 1,766,923 common stock purchase warrants. Each warrant was exercised to purchase one share of common stock for $3.25 per share. The warrants were issued as part of a $10.5 million financing completed in August 2016 and would have otherwise been exercisable until August 2021.
The exercise transactions were negotiated with certain warrant holders as a means of raising additional near-term working capital. In consideration for the exercise of the warrants, two warrant holders received new warrants to purchase the same number of shares purchased on exercise of the prior warrant, with an exercise price of $5.50 per share; another warrant holder received a new warrant to purchase the 50% of the number of shares purchased on exercise of the prior warrant, with an exercise price of $3.25 per share. The three warrants have a five-year term from the date of issuance.
A fourth warrant holder received (i) a new warrant to purchase 50% of the number of shares purchased on exercise of the prior warrant with an exercise price of $5.50 per share and (ii) a second new warrant to purchase 50% of the number of shares purchased on exercise of the prior warrant with an exercise price of $3.25 per share. These two warrants each have a two-year term from the date of issuance.
Following the exercise of the warrants, there were 31,313,200 shares of common stock outstanding and warrants to purchase an aggregate of 2,779,221 shares of common stock outstanding, including the warrants issued during August 2016 and February 2017 and the new warrants, with exercise prices ranging from $3.25 to $5.50. The proceeds from the warrant exercises strengthen OncoCyte’s balance sheet and will be used for general working capital purposes.
“The exercise of warrants by some of our largest shareholders provides additional working capital to advance the development of our novel liquid biopsy diagnostics for lung and breast cancer and prepare for the launch of our lung cancer diagnostic in the second half of 2017,” stated William Annett, President and CEO. “We appreciate the continued confidence in OncoCyte demonstrated by these warrant exercises and look forward to the achievement of additional significant milestones in 2017.”

[newguy49]

And this thing just continues to drift lower and lower.considering how close they are to starting to produce revenues I would think it could at least stay steady.

[Awl416]

Fun trade

[Tim501]

I guess it's pointless to ask the board if anyone saw the poster on Friday at SABCS?

[Tim501]

I think we saw some warrants exercised and so there was some selling of them on the way up and then on the way back down. This is common after the kind of insider fund raising that they did in late August. I took the opportunity to double my holdings at prices around $4 in the last couple weeks.

Sounds to me from the conference call after the close last night that the abstract for the big breast cancer readout is gonna be available some time Monday. They said in the call that the data was "very strong."

There were just barely any shares hitting the bids today and so it ticked up 10%. I'm so impressed with this leadership team and what they are doing. It sounds like the science is also working out, so if they get good data for breast to go with lung and bladder (cancer biopsies) can we say there could be some excitement?

We shall see. Enjoy the weekend longs!

Tim

[Akt1]

Why quick rise and then quick drop the past week or so -
over the past five days down about 2 dollars?

[Tim501]

Another 10% today on even higher volume than yesterdays. Still no news to be found anywhere. Looks like the warrants are just being exercised as shares are listed/sold on the orderly way UP. Keep it coming!

Tim

[Tim501]

There seems to be something good under the hood. Today's 13% move up came as big buyers had no choice but to push it higher to find shares. Two days ago the daily volume was 1.6K. Today was saw 1190K cross the tape. So Wednesday's volume was 75 times Monday's. No news to be found.

Today's volume was the second highest daily UP volume since the company's IPO/spin off from Biotime (BTX) in late 2015. On 4/4/16 OCX traded 218K on this headline (ONCOCYTE AND THE WISTAR INSTITUTE ANNOUNCE POSITIVE RESULTS IN THE DEVELOPMENT OF A BLOOD-BASED LUNG CANCER TEST)

We now know the science works and they are simply validating excellent standard of care worthy results (for lung cancer liquid biopsy test) due JAN 17. In DEC 16 we get early data for breast - same platform. They are already working a larger breast trial (hint -- good enough early data for them to continue for breast as the total platform looks strong).

Follow the money? The volume says buy, but no one seems to be here yet. Will they ever come?

The float is thin. BTX will likely sell some of their 14M shares and insiders have loaded up in late August on shares and reasonably priced options at $3.25. This should help the stock consolidate briefly after each leg up as we near late/early year data.

This is certainly a speculative play but results being validated were undeniably strong. So I've been wondering how the stock would trade in the silence as we near more data. I am presuming insiders are very confident as they could not dump shares easily if they suddenly had to, given the small float.

So given all that a 13% high volume pop today with no apparent news seems like a strong indicator -- and a buy signal, at least short term.

Tim

[Tim501]

At Aegis Growth Conference today it sounded like there was one guy in the audience but you got an earful if you listened to the company presentation (on their website soon I'm sure) and all the questions.

CEO said the data from their breast biopsy tests were obviously "exciting enough" to have them quickly start up a larger clinical trial. This data is embargoed now but will be announced in early December. Sounds like company has a big one-two punch with big data events in both DEC and JAN next. Then first product launch is on schedule for Q2 2017 which will begin to generate revenues.

Tim

[Tim501]

Big breakout today - up nearly 10% at the close. Volume was impressive.

Earlier this month the company announced this:

ONCOCYTE TO PRESENT INITIAL DATA ON ITS BREAST CANCER DIAGNOSTIC TEST AT THE PRESTIGIOUS SAN ANTONIO BREAST CANCER SYMPOSIUM

http://investors.oncocyte.com/news-releases/2016/09-08-2016-110057092

The event is DEC 9th. The release was a full 90 days before the presentation. That and the use of the word 'prestigious" seems like a big signal the company has great things to say, and with the validation of their successful data from the lung cancer study coming in JAN 17, the next few months could get very exciting. The market potential for their products seems substantial to me. I wonder if the Aegis investors that will hear them tomorrow (late) will think the same thing?

http://investors.oncocyte.com/news-releases/2016/09-20-2016-113014061

Importantly, where most bios are a total crap shoot - and nearly all fail at some point, this one seems to have success already in the bag -- at least on their lung cancer biopsy offering.

The float is so small, and most shares are tightly held, so like today -- any sign of aggressive buying pushes it up nicely. insiders have been big buyers lately and they are already handsomely rewarded.

Tim

[Tim501]

I own BTX, AST, and most recently OCX. I have owned BTX since it was BTIM trading below a buck. I think the latter two and therefore the "mothership" are going to do well over the coming years. As you likely know, all three have done fairly large cash raises in recent weeks, and each seem to be on the verge of rapidly ramping revenues as early as 2017. It has taken quite a while to get here. The data from AST (48% owned by BTX) this week was nothing short of astounding and that is a platform drug opportunity. With OCX, the data seems already conclusive for their lung cancer test, so we just have to await verification and then product ramp. Seems like everybody will want to use this new technology given current invasive and uncertainty issues with current standard of care.

Tim

[DeepDive]

A great company. Being a large BTX holder, I am watching closely, we own about half of the business. Seems like revenues in 2017, hopefully!

[Tim501]

Glad I found this one early. Like the favorable risk/reward chances for 2017 approval of their first (lung cancer test) offering with lots of other potential markets to follow. Recent finance raise and warrants from mainly insiders and others (Bailey is a big plus) means they have plenty of cash to get there without any other cash raises. I think this one is a hidden gem and any good news at all will send the thinly traded stock surging.

[DeepDive]

http://tinyurl.com/hyxwl9r

Take notice, no one invests 750,000$ without high conviction his investment will pan out

[DeepDive]

New board member, from Asterias, buying 750,000$ stock. That is bullish.

[poonch1ne]

is this halted?

[nuketheshorts]

OncoCyte Starts Trading on NYSE MKT
On December 31,2015. On 12/31/15
Biotime (BTX) distributed about 4.8 million
OncoCyte shares to its shareholders.